Revolution Medicines RVMD 深 滬
已收盤 10-17 16:00:00 美东时间
54.10
+4.420
+8.90%
華盛通- 最 高56.15
- 今 開52.76
- 成交量 458.66万股
- 最 低 52.40
- 昨 收 49.68
- 總市值 90.37亿
- 52周最高 62.40
- 市盈率 靜 --
- 換手率 2.75%
- 52周最低 29.17
- 委 比 -56.01%
- 總股本 1.67亿
- 歷史最高 62.40
- 量 比 2.26
- 振 幅 7.55%
- 歷史最低 14.08
- 每 手 1
- 風險率 6.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股收盘：区域银行信贷恐慌退潮，贸易紧张局势缓和，三大指数集体收涨
区域银行信贷恐慌退潮，贸易紧张局势缓和，三大指数集体收涨；特斯拉收涨2.46%，苹果涨1.96%；甲骨文大跌近7%，创1月份以来最大单日跌幅>>
10-18 09:25
'No Need To Sell' Martin Marietta Materials, Cramer Says: 'It's Just A Great Long-Term Hold'
Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a price target of $620.
10-17 19:46
Achieve, Disc, Revolution among winners of initial FDA national priority vouchers
Achieve Life Sciences (NASDAQ:ACHV), Disc Medicine (NASDAQ:IRON), and Revolution Medicines (NASDAQ:RVMD) have been selected among the first nine recipients of the FDA Commissioner’s National Priority ...
10-17 19:12
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
FDA Awards First-Ever National Priority Vouchers to Nine Sponsors
https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors
10-17 05:27
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
Revolution Medicines announced that the FDA granted a non-transferrable priority review voucher for its RAS(ON) inhibitor daraxonrasib under the CNPV pilot program. Daraxonrasib is being tested in Phase 3 trials for pancreatic and non-small cell lung cancer. The company highlights the potential of daraxonrasib to address unmet needs in RAS-addicted cancers, with data expected in 2026. The FDA's CNPV program aims to accelerate development of drugs...
10-17 00:00
Stifel Reinstates Buy on Revolution Medicines, Announces $85 Price Target
Stifel analyst Laura Prendergast reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $85 price target.
10-16 21:46
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Revolution Medicines appoints Alan Sandler, M.D., as Chief Development Officer and adds regional leaders to support global commercial capabilities. Dr. Sandler, a recognized oncology leader, brings extensive experience in drug development. The company also appointed Alicia Gardner and Gerwin Winter as U.S. and European regional general managers to prepare for potential approvals and launches of RAS(ON) inhibitors, including daraxonrasib, targetin...
09-29 13:00
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
